Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.

Gesche Tallen; Richard Ratei; Georg Mann; Gertjan Kaspers; Felix Niggli; Alexandr Karachunsky; Wolfram Ebell; Gabriele Escherich; Martin Schrappe; Thomas Klingebiel; Ruediger Fengler; Günter Henze; Arend von Stackelberg

Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.

Standard

Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. / Tallen, Gesche; Ratei, Richard; Mann, Georg; Kaspers, Gertjan; Niggli, Felix; Karachunsky, Alexandr; Ebell, Wolfram; Escherich, Gabriele; Schrappe, Martin; Klingebiel, Thomas; Fengler, Ruediger; Henze, Günter; von Stackelberg, Arend.

in: J CLIN ONCOL, Jahrgang 28, Nr. 14, 14, 2010, S. 2339-2347.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Tallen, G, Ratei, R, Mann, G, Kaspers, G, Niggli, F, Karachunsky, A, Ebell, W, Escherich, G, Schrappe, M, Klingebiel, T, Fengler, R, Henze, G & von Stackelberg, A 2010, 'Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.', J CLIN ONCOL, Jg. 28, Nr. 14, 14, S. 2339-2347. <http://www.ncbi.nlm.nih.gov/pubmed/20385996?dopt=Citation>

APA

Tallen, G., Ratei, R., Mann, G., Kaspers, G., Niggli, F., Karachunsky, A., Ebell, W., Escherich, G., Schrappe, M., Klingebiel, T., Fengler, R., Henze, G., & von Stackelberg, A. (2010). Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J CLIN ONCOL, 28(14), 2339-2347. [14]. http://www.ncbi.nlm.nih.gov/pubmed/20385996?dopt=Citation

Vancouver

Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J CLIN ONCOL. 2010;28(14):2339-2347. 14.

Bibtex

@article{96b11d341fc34677b495b53aa9f5e0ef,

title = "Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.",

abstract = "The multicenter trial ALL-REZ BFM (ie, Acute Lymphoblastic Leukemia Relapse Berlin-Frankfurt-M{\"u}nster) 90 was designed to improve prognosis for children with relapsed acute lymphoblastic leukemia (ALL) by time-to-relapse- and site-of-relapse-adapted stratification and by introduction of novel chemotherapy elements and to evaluate new prognostic parameters in a large, population-based cohort.",

keywords = "Humans, Male, Female, Risk Factors, Adolescent, Treatment Outcome, Europe, dosage, Child, Risk Assessment, Time Factors, Disease-Free Survival, Proportional Hazards Models, Child, Preschool, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Etoposide administration, Recurrence, Chi-Square Distribution, Stem Cell Transplantation, Cranial Irradiation, Cytarabine administration, Drug Administration Schedule, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Radiotherapy, Adjuvant, Humans, Male, Female, Risk Factors, Adolescent, Treatment Outcome, Europe, dosage, Child, Risk Assessment, Time Factors, Disease-Free Survival, Proportional Hazards Models, Child, Preschool, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Etoposide administration, Recurrence, Chi-Square Distribution, Stem Cell Transplantation, Cranial Irradiation, Cytarabine administration, Drug Administration Schedule, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Radiotherapy, Adjuvant",

author = "Gesche Tallen and Richard Ratei and Georg Mann and Gertjan Kaspers and Felix Niggli and Alexandr Karachunsky and Wolfram Ebell and Gabriele Escherich and Martin Schrappe and Thomas Klingebiel and Ruediger Fengler and G{\"u}nter Henze and {von Stackelberg}, Arend",

year = "2010",

language = "Deutsch",

volume = "28",

pages = "2339--2347",

journal = "J CLIN ONCOL",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "14",

}

RIS

TY - JOUR

T1 - Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.

AU - Tallen, Gesche

AU - Ratei, Richard

AU - Mann, Georg

AU - Kaspers, Gertjan

AU - Niggli, Felix

AU - Karachunsky, Alexandr

AU - Ebell, Wolfram

AU - Escherich, Gabriele

AU - Schrappe, Martin

AU - Klingebiel, Thomas

AU - Fengler, Ruediger

AU - Henze, Günter

AU - von Stackelberg, Arend

PY - 2010

Y1 - 2010

N2 - The multicenter trial ALL-REZ BFM (ie, Acute Lymphoblastic Leukemia Relapse Berlin-Frankfurt-Münster) 90 was designed to improve prognosis for children with relapsed acute lymphoblastic leukemia (ALL) by time-to-relapse- and site-of-relapse-adapted stratification and by introduction of novel chemotherapy elements and to evaluate new prognostic parameters in a large, population-based cohort.

AB - The multicenter trial ALL-REZ BFM (ie, Acute Lymphoblastic Leukemia Relapse Berlin-Frankfurt-Münster) 90 was designed to improve prognosis for children with relapsed acute lymphoblastic leukemia (ALL) by time-to-relapse- and site-of-relapse-adapted stratification and by introduction of novel chemotherapy elements and to evaluate new prognostic parameters in a large, population-based cohort.

KW - Humans

KW - Male

KW - Female

KW - Risk Factors

KW - Adolescent

KW - Treatment Outcome

KW - Europe

KW - dosage

KW - Child

KW - Risk Assessment

KW - Time Factors

KW - Disease-Free Survival

KW - Proportional Hazards Models

KW - Child, Preschool

KW - Antineoplastic Combined Chemotherapy Protocols therapeutic use

KW - Etoposide administration

KW - Recurrence

KW - Chi-Square Distribution

KW - Stem Cell Transplantation

KW - Cranial Irradiation

KW - Cytarabine administration

KW - Drug Administration Schedule

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy

KW - Radiotherapy, Adjuvant